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patients who recover to their pre-hospitalization EPO dose, post-hospitalization
ESA dose increases frequently persist for several months, possibly due to
missed ESA doses, lower Hb from hospital-related phlebotomy, or increased
inflammatory states post-hospitalization. Strategies to address the causes of
this should be evaluated.
PUK30
ONCE MONTHLY ERYTHROPOIESIS STIMULATING AGENT (ESA) DOSING MAY
REDUCE ESA UTILIZATION COMPARED TO THRICE-WEEKLY ESA DOSING
Bond TC1, Rubin JL1, Wang X1, Yang A2
1DaVita Clinical Research, Minneapolis, MN, USA, 2Affymax, Palo Alto, CA, USA
OBJECTIVES: US dialysis centers typically dose ESA at every session (3x/wk), en-
abling frequent titrations. A once-monthly ESA is currently under FDA consider-
ation. We recently demonstrated that more frequent Hb measurements and dose
titrations are associated with higher ESA utilization. We developed an economic
model to quantify the potential impact of switching from a 3x/wk ESA to one dosed
monthly, due to fewer titrations and fewer Hb measurements, not considering
other efficiencies (e.g., reduced administrations). METHODS: A cost-offset model
estimated total ESA utilization and cost for monthly vs. 3x/wk dosing. Utilization
inputs were derived from a retrospective study of prevalent ( 120 days), adult (
18 years old) hemodialysis patients (n78,730), dialyzing at a large dialysis organi-
zation between 01/01/09-12/31/10. Patients dosed 3x/wk experience 1.1 dose titra-
tions and 2.9 Hb measurements on average per patient-month. Each additional
monthly dose titration is associated with a 24.1% (95% CI: 21.5%-26.4%) increase in
total ESA dose. Based on once-monthly ESA vs. 3x/wk ESA data (Provenzano et al.,
ASN 2011), we projected patients on a once-monthly ESA would experience 0.8
titrations and 1 Hb measurement per month, and projected savings-based reduc-
tions ofmean titrations and tests. Price (derived from published sources), dose and
clinical equivalence were assumed across ESAs. Model outcomes include incre-
mental utilization and cost. RESULTS: The model predicts that switching patients
to monthly ESA could result in a 7.95% (95% CI; 7.10%–8.73%) reduction in per-
patient/month ESA utilization. This translates into savings of 5,322 (95% CI; 4,748–
5,839 U) ESA units/month/patient and $52.37 (95% CI; $46.72–$57.46) per-patient/
month. For an average facility (96 patients), we estimated ESA savings of 510,934
U/month and cost savings of $5,028/month. CONCLUSIONS: The model predicts
that increasing the interval between ESA dose adjustments, based upon the FDA
approval and administration of a once monthly ESA, could decrease ESA utiliza-
tion.
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HOW COMMON IS CO-OCCURRING ED AND BPH IN A HEALTH CARE CLAIMS
DATABASE?
Schoenfeld MJ, Shortridge E, Emmick JT, Shen W, Cui Z
Eli Lilly and Company, Inc., Indianapolis, IN, USA
OBJECTIVES: in themedical literature of co-occurrence of erectile dysfunction (ED)
and benign prostatic hyperplasia (BPH) in men range from 20 to 80% depending on
age, definition and severity of symptoms, and other patient characteristics studied.
This study identifies the co-occurrence of these conditions, using healthcare insur-
ance claims data, to provide payers with an estimate of these burdensome
conditions. METHODS: Patients with ED and/or BPH were identified by diagnostic
codes in the Thomson Reuters MarketScan® Database from January 1, 2007 to June
30, 2010. Patients in the samplewere categorized as having BPH, ED, or co-occurring
BPH and ED, and were examined by age group (younger men aged 40-64 and older
men 65 and above). RESULTS: Of 685,270 men who met eligibility criteria, 531,486
(77.6%) were younger men and 153,784 (22.4%) were older men. Overall, 416,228
(60.7%) were diagnosed with ED (mean age 52.5), 336,432 (49.1%) were diagnosed
with BPH (mean age 62.5), and 67,390 (9.8%) were diagnosed with both ED and BPH
(mean age 60.3) in the study period. Among youngermen, co-occurring ED and BPH
accounted for 9.1% inmenwith ED or BPH, 13.4% inmenwith ED and 21.9% inmen
with BPH. Among older men, co-occurring ED and BPH accounted for 12.5% in men
with ED or BPH, 34.3% inmenwith ED, and 16.5% inmenwith BPH. CONCLUSIONS:
In this analysis, co-occurring ED and BPH varied in men by age. In younger men,
co-occurring ED and BPH accounted for a greater percentage of those in the BPH
cohort, whereas, in oldermen, co-occurrence accounted for a greater percentage of
the ED cohort. This may be a reflection of coding in the claims data or may suggest
that men may not seek treatment for both conditions or prioritize conditions dif-
ferently as they age.
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LOWER CASE MIX ADJUSTERS ARE ASSOCIATED WITH LOWER
ERYTHROPOIESIS-STIMULATING AGENT (ESA) AND OTHER BUNDLED COSTS
Sibbel SP1, Rubin JL1, Yang A2
1DaVita Clinical Research, Minneapolis, MN, USA, 2Affymax, Palo Alto, CA, USA
OBJECTIVES: The CMS dialysis prospective payment system (PPS) uses patient
characteristics and comorbidities to calculate payments. The final list of multipli-
ers (case-mix adjusters; CMAs) was effective January 2011. We assessed patient
CMAs and their relationship to ESA and other resource utilization covered by the
PPS. METHODS: We conducted a retrospective analysis of adult (3 18 yrs old) he-
modialysis patients at a large dialysis organization from 1/1/2011-6/30/2011. Pa-
tient CMAs, ESA utilization, other bundled costs (IV medications and laboratory
tests), and number of sessions attendedwere assessed for associationwith the PPS
composite CMA. Differences in utilization were assessed in a stratified generalized
linear model analysis across all months. Outlier payments were added to the base-
payment for very high-cost patients. RESULTS: CMA values were strongly posi-
tively associated with per-session ESA utilization and per-session costs for other
bundle components (p 0.001). ESA dose was 1.24 times higher for patients in the
highest CMA category (1.5) relative to patients in the lowest CMA category (1.0).
Patients in the lowest CMA category had mean additional bundled costs of $8.76
and patients in the highest category had a cost of $11.99 dollars (p 0.001). CMA
valueswere inversely associatedwith number of attended sessions (11.75 attended
sessions in the lowest CMA group vs. 10.16 in the highest; p 0.001). ESA use
accounted for the highest proportion of total costs (0.598). CONCLUSIONS: This
study shows a strong association between CMAs and ESA utilization, additional
treatment costs, and missed sessions. Monthly average CMA values cluster tightly
around 1.0, indicatingmost patients donot qualify for CMS-definedCMAs; however
the strong association between CMA and resource utilization suggests an associa-
tion between the CMA level and patients’ treatment cost , therefore CMS should
implement processes to help dialysis providers gain access to the underlying CMA
conditions and diagnoses.
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COST-UTILITY ANALYSIS OF ALTERNATIVE TREATMENTS FOR MODERATE
GRADE VESICOURETERAL REFLUX
Qureshi Z1, Bennett C2
1University of South Carolina, Columbia, SC, USA, 2South Carolina College of Pharmacy,
University of South Carolina, Columbia, SC, USA
OBJECTIVES: To provide a cost-effectiveness analysis of treatments for moderate
grade vesicoureteral reflux (VUR), an illness that accounts for an estimated $100
million in healthcare expenditures. Treatment options include antibiotics, nonsur-
gical endoscopic injection with dextranomer/hyaluronic acid, and surgical repair.
METHODS:A systematic review usingMEDLINE (search terms VUR, treatment, and
cost) for 2006- 2011. RESULTS: Dextranomer/hyaluronic acid injection is the more
cost-effective option compared to ureteral reimplantation when success rates for
dextranomer/hyaluronic acid injection are 58% per ureter for patients with unilat-
eral reflux and 75% per ureter for bilateral reflux. If increasing grades of reflux
require increasing volumes of dextranomer/hyaluronic acid, success rates of 73%
for unilateral reflux and 94% for bilateral reflux represent the break-point for cost-
effectiveness. In models where dextranomer/hyaluronic acid injection is repeated
if VUR does not resolve after initial injection, break-even success rates are 11% and
60% with unilateral reflux if success rates of initial injections were 70% and 55%,
respectively. Break-even success rates for second dextranomer/hyaluronic acid
injections are 29% and 77% per ureter with bilateral reflux, if success rates of initial
injections are 70% and 55%, respectively. Based on 2011 epidemiologic estimates of
5580 children who are candidates for VUR treatments, dextranomer/hyaluronic
acid injection endoscopic injections and clinical outcome success rates as reported
in recent studies, potential annual savings with dextranomer/hyaluronic acid
range from $1.5 million to $23 million. CONCLUSIONS: A nonsurgical approach is
potentially associated with beneficial outcomes and cost-effectiveness. Longer-
term studies are needed to refine the range of outcomes and downstream costs.
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VALIDATION OF ICD-9 CODES FOR THE IDENTIFICATION OF PATIENTS WITH
STAGE 3-5 CHRONIC KIDNEY DISEASE IN ADMINISTRATIVE CLAIMS DATA
Grabner M, Chen Y, Palli SR, Quimbo RA
HealthCore, Inc., Wilmington, DE, USA
OBJECTIVES: Testing the validity of ICD-9-CM codes to identify diabetic patients
with stage 3-5 chronic kidney disease (CKD) in claims data. METHODS: We con-
ducted a cross-sectional study using claims from a large commercial health plan.
Patients meeting the following criteria were included: 1) diagnosis of type 2 diabe-
tes; 2) 12 months of continuous health plan eligibility; and 3) 2 non-zero serum
creatinine lab values, at least 90 days apart, between January 1, 2004 and June 30,
2011.We identified 12 ICD-9-CM code groups potentially indicative of CKD stage 3-5
and validated them against a “gold standard”, defined as two laboratory claims, at
least 90 days apart, with an estimated glomerular filtration rate (eGFR) 60 mL/
min. eGFR was calculated using the CKD Epidemiology Collaboration equation and
the Modification of Diet and Renal Disease (MDRD) equation. We calculated sensi-
tivity, specificity, positive predictive value (PPV) and negative predictive value for
the selected codes. Exact binomial 95% confidence intervals (CIs) were derived, and
codes with a PPV whose lower CI bound was  80% were considered valid.
RESULTS: The study sample consisted of 383,970 patients. Approximately 16% of
the sample (N61,052) had stage 3-5 CKD based on the “gold standard”. ICD-9-CM
codes for chronic renal failure, stage 3-5 (585.3-5), had a PPV of 84.2% (CI: 83.7% -
85.7%). ICD-9-CM code 585.6, used for end-stage renal disease, had a PPV of 84.7%
(CI: 83.6% - 85.7%). ICD-9-CM code 285.21, used to describe anemia in CKD, had a
PPV of 85.4% (CI: 84.6% - 86.2%). For the remaining code groups, PPV ranged from
50% to 78%, with CIs of  2 percentage points. Similar results were obtained when
eGFR was calculated using the MDRD equation. CONCLUSIONS: This cross-sec-
tional validation study suggests that diabetic patients with stage 3-5 CKD can be
accurately identified in administrative claims data using selected ICD-9-CM codes.
PUK35
EQ-5D (UK AND THAI PREFERENCE WEIGHTS), SF-6D, AND VAS SCORES IN
DIALYSIS THAI PATIENTS
Thaweethamcharoen T, Vasuvattakul S, Noparatayaporn P
Mahidol University, Bangkok, Thailand
OBJECTIVES: To evaluate the utility scores from EQ-5D (UK and Thai preference
weight), VAS, and SF-6D in dialysis patients and to compare the correlation be-
tween these scores and the disease specific scores using KDQOL-36. METHODS:
This study was a cross-sectional study. A Face-to-face interviews using EQ-5D and
KDQOL-36 were conducted from April to August 2011 with 160 hemodialysis pa-
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tients and 62 peritoneal-dialysis patients at Siriraj hospital. Utility scores and the
correlation coefficientwith KDQOL-36were calculated. Percentages of respondents
with the ceiling and floor effects were compared for each of the different measure-
ment tools. RESULTS: Patient samples had a mean age of 60.2014.84 years. Mean
duration of dialysis were 7.445.42 years for hemodialysis patients, and 1.821.22
years for peritoneal-dialysis patients. The mean SF-6D score (0.7830.164) was
significantly higher than EQ-5D (UK: 0.7520.309, Thai: 0.6910.314), and VAS
(0.6660.196) scores. Most of the kidney specific dimensions were better correlated
with SF-6D than EQ-5D (UK and Thai preference weight) and VAS scores. Ceiling
effects were observed in the EQ-5D concerning both UK and Thai preference
weight, due to the fact that the EQ-5D differentiates less in the better health states,
whereas the floor effects were not clearly observed in any instrument tools.
CONCLUSIONS: SF-6D presented better correlation with kidney specific scales
while the responsiveness of EQ-5D utility scores was poor. One explanation might
be a ‘‘ceiling effect’’ of the EQ-5D. These findings implied that SF-6D utility scores
could reflect HRQoL status of dialysis patients better than EQ-5D and VAS.
PUK36
USING BOOTSTRAP CONFIDENCE INTERVALS TO COMPARE RELATIVE
VALIDITY COEFFICIENTS: AN EXAMPLE WITH PRO MEASURES OF CHRONIC
KIDNEY DISEASE (CKD) IMPACT
Deng N, Ware J
University of Massachusetts Medical School, Worcester, MA, USA
OBJECTIVES: To evaluate bootstrap techniques in comparing the validity of PRO
measures in discriminating among CKD patients and responding to longitudinal
changes.METHODS: The Kidney Disease Impact Scale (KDIS), CKD-specific legacy
(KDQOL Burden, Symptom, and Effect) and generic health (SF-12) scales were ad-
ministrated to 453 patients and re-administered to 110 patients after threemonths.
ANOVA-based relative validity (RV) coefficients were used to compare how well
each scale discriminated between three clinically-defined groups ordered in terms
of severity (Dialysis Stage 3-5 Transplant), and how responsive each scale was
to changes over time for self-evaluated Better, Same and Worse groups. Bootstrap
was used to construct confidence intervals (CIs) to determine whether the differ-
ences in RVs were significant in comparisons between each scale and the best
legacy measure - KDQOL Burden. Sample size, number of bootstrap iterations, and
type of CIs were varied to evaluate their impacts on CI using real and artificial data.
RESULTS: The sample size played a substantial role. 300 people for 3 groups were
suggested as theminimumnumber tomakemeaningful comparisons betweenRVs
using CI. Number of bootstrap replications (100 to 10,000) did not show an obvious
effect on bootstrap standard error, although 300 showed improvement over 100 on
CI. The bias-corrected and accelerated (BCa) type of CI was preferred for correcting
both bias and skewness in bootstrap distribution and for producing narrower CIs.
Using 95% CI and 300 sample size, differences in RVs were non-significant in com-
parisonswith KDQOL-Burden (RV1) for the following scales: SF-12 PCS (RV.6), PF
(RV.7), RP (RV .77), KDQOL-Effect (RV.99), and KDIS (RV1.13). CONCLUSIONS:
Bootstrapping appears to be valuable in testing the significance of differences in
the relative validity of these PRO measures from a statistical perspective. Samples
of 100 per group compared and 300 bootstrap replications are recommended.
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PRM1
COMPLIANCE ON THE CONSOLIDATED STANDARDS OF REPORTING TRIALS
(CONSORT) GUIDELINES IN RANDOMIZED CONTROLLED TRIALS
Godwin OP1, Dyson B1, Park SY1, Lee E2
1Howard University Center for Minority Health Services Research, College of Pharmacy,
Washington, DC, USA, 2Howard University, Washington, DC, USA
OBJECTIVES: The Consolidated Standards of Reporting Trials (CONSORT) state-
mentwas published in 2001 and updated in 2010, strongly recommended the use of
CONSORT diagram to report the flow of participants through each stages of the
trial. This studywas conducted to describe the level of compliance of the published
clinical trial in following the CONSORT recommendations and to estimate preva-
lence of the compliance.METHODS: A systematic literature search of all random-
ized controlled trials of anti-infectious agents published in the top 10 general med-
icine journals and top 5 infectious disease journals published in 2010. The journals
include: The New England Journal of Medicine, Journal of the American Medical
Association, British Medical Journal (Clinical Research Ed), Archives of Internal
Medicine, PloS Medicine, Annals of Internal Medicine, Clinical Infectious Diseases,
the Journal of Infectious Diseases, the Lancet Infectious Diseases, AIDS, Emerging
Infectious Diseases Journal, Annual Review of Medicine, Canadian Medical Associ-
ation Journal, and Annals of Medicine Journal. Each article was reviewed by two
independent investigators based on the reporting criteria recommended by the
CONSORT statement. Exclusion criteria included non-randomized control studies,
and studies not including intervention or control group. RESULTS: The study iden-
tified 129 published articles using explicit criteria on Medline search. A total of 73
randomized controlled trials met the inclusion criteria. Of 73 studies, 55 (75.34%)
articles included the CONSORT diagram. A comprehensive depiction of the CON-
SORT guidelines will be made and detail descriptions on the compliances will be
presented by journal types during the presentation. CONCLUSIONS: Randomized
controlled trials published in the top 10 general medicine journals and the top 5
infectious diseases journals in 2010 contain significant deficiencies in reporting the
CONSORT flow chart. The clarity and the completeness of a study could be im-
proved if the CONSORT statement is followed as prescribed.
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NETWORK META-ANALYSIS OF INDIVIDUAL AND AGGREGATE LEVEL DATA
Jansen JP1, Cope S2
1Mapi Consultancy / Tufts University School of Medicine, Boston, MA, USA, 2Mapi Consultancy,
Boston, MA, USA
OBJECTIVES: Network meta-analysis is often performed with aggregate level data
(AD). A challenge with meta-regression models using AD is that the association
between a patient level covariate and relative treatment effects of the compared
interventions at the study level may not reflect the individual level effect-modifi-
cation. In this paper, non-linear network meta-analysis models for combining in-
dividual patient data (IPD) and AD are presented to reduce bias and uncertainty of
treatment effects in the presence of heterogeneity due to patient characteristics.
METHODS: The first method uses the same model form for IPD and AD. With the
second method, the model for AD is obtained by integrating an underlying IPD
model over the joint within-study distribution of covariates. With a simple simu-
lation study the twomodeling approaches are compared. RESULTS:Having IPD for
a subset of studies improves estimation of treatment effects with network meta-
analysis in the presence of patient level heterogeneity and inconsistency. Of the
two proposed non-linear models for combining IPD and AD, the second approach
seems less affected by bias. Additional studies, however, are needed to assess the
value of both methods. CONCLUSIONS: Overall, for network meta-analysis it is
recommended to use IPD when available, rather than treating all studies as AD.
PRM3
THE ENSEMBLE MINIMUM DATASET: A NEW INSTRUMENT TO EXPLORE
HETEROGENEITY OF TREATMENT EFFECT
Brenneman SK1, Brekke L1, Bancroft TJ1, Shen W2, Paczkowski R2, Berger M1, Kaplan SH3,
Greenfield S3, Buesching DP2
1OptumInsight, Eden Prairie, MN, USA, 2Eli Lilly and Company, Inc., Indianapolis, IN, USA,
3University of California Irvine, Irvine, CA, USA
OBJECTIVES: To develop an instrument that identifies patient groups likely to have
differing responses to treatment, we tested candidate measures thought to dis-
criminate differences among patients in 4 disease cohorts: type 2 diabetes (T2D),
knee osteoarthritis (OA), ischemic heart disease (IHD) and heart failure (HF).
METHODS: Eligible patients identified from claims data were sent a survey includ-
ing 17 scales hypothesized to comprise 4 domains (health profile, personality, be-
havior, life context). Proxies for treatment response were patient-reported global
impression of disease severity (PGIS), global impression of improvement (PGII), and
administrative claims health care utilization (HCU). Variability (SD) and internal
consistency (Cronbach’s alpha) of the scales were examined, as was discriminant
validity against strata of PGIS, PGII and HCU. Conceptual overlap, correlations
among scales, and factor loading within and across domains were examined.
Scales with desirable properties were included in the final instrument. Discrimi-
nant validity of proposed domains was analyzed by ANOVA adjusted for age and
gender. Multiple regression models were used to assess the associations between
the proposed domains and outcomes. RESULTS: A total of 723 T2D patients, 682
knee OA patients, 632 IHD patients, and 588 HF patients completed the survey. The
initial instrument was refined to 7 scales across 3 domains. The health profile
domain significantly discriminated 100% of the strata across disease cohorts (each
P0.001). Personality and behavior domains also discriminated strata well (75%
and 50%, respectively). Alone, the health profile significantly discriminated strata
across disease cohorts in multivariate analyses (each P 0.001). In models includ-
ing all 3 domains, the health profile remained the most important contributor.
CONCLUSIONS: The final ENSEMBLE MDS instrument discriminated among pa-
tients with varied diseases; the health profile provided much of the ability to dis-
criminate. Further research is needed to assess the instrument’s potential to pre-
dict health state changes due to trial interventions.
PRM4
ENHANCING THE HEALTH ECONOMIC VALUE OF RETROSPECTIVE AND
PROSPECTIVE REAL-WORLD STUDIES WITH PHARMACOGENOMIC TESTING:
OPPORTUNITIES AND CHALLENGES ASSOCIATED WITH AN INTEGRATED
PERSONALIZED MEDICINE APPROACH
Payne KA1, Frueh FW2, Sohal J3
1United BioSource Corporation, Dorval, QC, Canada, 2Medco Health Solutions, Inc., Franklin
Lakes , NJ, USA, 3United BioSource Corporation, Hammersmith, UK
OBJECTIVES: A better understanding of a patient’s genetic make-up through phar-
macogenomic testing can help achieve improved and more predictable patient
outcomes, often at equal or lower total treatment cost. Stakeholders including
physicians, payers andpatients alike can benefit from real-world data that identify,
a priori, the sub-groups of patients for whom treatments are likely to be more
cost-effective.METHODS: Retrospective and prospective case study designswithin
which pharmacogenomic testing has been integrated are presented. Design pa-
rameters are described and opportunities and challenges alongside strategies for
resolution are delineated. RESULTS: As the genetic make-up of a patient does not
change, pharmacogenomic testing can be done at any point in time andpairedwith
historical and/or newly collected patient level data. Retrospective studies are
highly efficient as they do not require costly longitudinal follow-up, whereas pro-
spective studies including registries offer the opportunity to augment pharmacog-
enomic and other study data with patient and physician reported outcomes not
otherwise available in the medical chart. Main challenges associated with either
approach include optimizing the patient informed consent process, streamlining
the logistics associated with pharmacogenomic testing and storage in the usual
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